ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies
SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immun...
Shanghai Pharma Global Standard Stock Incentive Scheme to Push Innovation Refiled for Approval
SHANGHAI, Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent...
Shanghai Pharma Unveils Stock Incentive Plans to Accelerate Global Ambition
SHANGHAI, April 15, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holdings Co. Ltd. (Shanghai Pharma or "the Company") (601607.SH) (2067.HK), a major Chinese pharmaceutical group, has unveiled stock option incentive plans in a milestone move designed to accelerate restructuring and boost global c...
Bracco Imaging and Shanghai Pharmaceuticals join forces in the field of ultrasound
MILAN, May 22, 2018 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Shanghai Pharmaceuticals Holding Co. Ltd., a leading pharmaceutical group inChina - focused on providing innovative drugs in the field of oncology, infectious and cardiovascular diseases - have s...
Shanghai Pharmaceuticals Achieves Rapid Business Growth for 3Q2014; Realized Double-Digit Growth of Revenue and Profit
HONG KONG, Oct. 29, 2014 /PRNewswire/ --Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both ph...
Shanghai Pharmaceuticals Achieves Double-Digit Growth of Revenue and Profit for 1H2014
HONG KONG, Aug. 30, 2014 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd.("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both ph...
Shanghai Pharmaceuticals Records a Growth of 8.6% in Operating Revenue in 1Q2014
HONG KONG, April 28, 2014 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pha...
Maintained Steady Growth Results, Confirmed 3-Year Development Plan, Shanghai Pharmaceuticals Achieved over 15% Growth in Operating Income in 1H2013
HONG KONG, Aug. 23, 2013 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), today announced its interim results for the first half of 2013. In the first half of 20...
Shanghai Pharmaceuticals Joins hands with the Secondary Military Medical University to Explore the New Medicine R&D and Translational Medicine Field
HONG KONG, July 31, 2013 /PRNewswire/ -- Nowadays, Translational Medicine has become the buzzword in the field of pharmaceutical research and development. To jointly promote the development of this emerging field of research, Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or ...
Shanghai Pharmaceuticals Announces 1st Quarterly Results of 2013
-- Operating Revenue Surges 17.6% -- Change of Board of Directors On Schedule HONG KONG, April 29, 2013 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), to...
Shanghai Pharmaceuticals Announces 2012 Third Quarterly Report
Operating Revenue & Net Profit Attributable to Shareholders of the Parent Company Surges 27.01% & 12.15% respectively HONG KONG, Oct. 29, 2012 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; ...
Shanghai Pharmaceuticals Group Calls AGM Adjust Use of Proceeds & Strengthen Core Business
HONG KONG, May 31, 2012 /PRNewswire-Asia/ -- Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals Group" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), today called its 2011 annual general meeting (AGM). The number of attendees rea...
